In June 2023, the Company lowered 2023 non-GAAP adjusted operating expense guidance to $350-$370 million, inclusive of restructuring costs. The Company remains on track to achieve an expected net reduction in annual non-GAAP adjusted operating expenses of approximately $140 million – relative to updated 2023 non-GAAP adjusted operating expense guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Meta upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- H.C. Wainwright double upgrades Intercept on potential in PBC
- Intercept upgraded to Buy from Sell at H.C. Wainwright
